Keyphrases
13-valent Pneumococcal Conjugate Vaccine (PCV13)
10%
30-day Mortality
7%
Antibiotic Resistance
7%
Antibiotic Use
9%
Antibiotics
6%
Antimicrobial Use
6%
Bacteremia
14%
Bloodstream Infection
6%
Clinical Characteristics
9%
Comorbidity
7%
Confidence Interval
14%
COVID-19
18%
Drug Resistance
6%
Empirical Therapy
7%
Encephalitis
7%
Escherichia Coli
7%
Ethiopian
7%
Highly Active Antiretroviral Therapy (HAART)
6%
HIV Patients
22%
HIV-1 Subtype C
7%
HIV-positive
7%
Hospital Admission
9%
Hospitalization
7%
Hospitalized Patients
16%
Human Immunodeficiency Virus Type 1 (HIV-1)
32%
Independent Risk Factors
6%
Infected Patients
7%
Invasive Pneumococcal Disease
12%
Israel
100%
Israeli
23%
Men Who Have Sex with Men
7%
Methicillin-resistant Staphylococcus Aureus
18%
Nationwide Surveillance
9%
Odds Ratio
22%
Older Adults
6%
PCV7
6%
Quinolones
9%
Randomized Controlled Trial
7%
Retrospective Cohort Study
7%
Risk Behavior
9%
Risk Factors
19%
Staphylococcus Aureus Bacteremia
6%
Surgical Site Infection
9%
Surveillance Studies
6%
Travellers
6%
Vaccination
7%
Viral Load
9%
Virus
12%
West Nile Fever
15%
West Nile Virus Infection
7%
Pharmacology, Toxicology and Pharmaceutical Science
2009 H1N1 Influenza
6%
Adverse Event
8%
Antibiotic Agent
6%
Antibiotic Therapy
5%
Antibiotics
28%
Antiinfective Agent
15%
Aztreonam
6%
Bacteremia
18%
Bloodstream Infection
9%
Cohort Study
22%
Combination Therapy
6%
Coronavirinae
6%
Disease
18%
Enterobacteriaceae
6%
Extended Spectrum Beta Lactamase
5%
HIV
29%
Infection
23%
Methicillin-Resistant Staphylococcus Aureus
10%
Mortality Rate
5%
Pneumococcal Infection
12%
Pneumococcus Vaccine
6%
Pneumocystis Jiroveci
6%
Prevalence
9%
Quinolone Derivative
6%
Randomized Controlled Trial
8%
Rituximab
6%
SARS Coronavirus
6%
West Nile Fever
9%
Medicine and Dentistry
Antibiotic Therapy
10%
Antibiotics
8%
Antiretroviral Therapy
9%
Bacteremia
8%
Bloodstream Infection
9%
Carbapenem
5%
Cohort Analysis
12%
Combination Therapy
6%
COVID-19
12%
Disease
11%
Drug Resistance
10%
Encephalitis
6%
Enterobacteriaceae
6%
Extended Spectrum Beta Lactamase
5%
Human Immunodeficiency Virus
38%
Human Immunodeficiency Virus Infection
6%
Infection
16%
Mortality Rate
9%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Odds Ratio
7%
Omicron Coronavirus Variant
6%
Pneumococcal Infection
9%
Pneumocystis Jirovecii
6%
Prevalence
8%
Rituximab
6%
Serotype
5%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Surgical Infection
9%
Virus Infection
8%
West Nile Fever
12%
West Nile Virus
9%